SK Holdings C&C announced that the company signed an MOU on the development of the Artificial Intelligence Aibril Infectious Disease Diagnosis Service based on Watson, an highly advanced artificial intelligence technology with KU-MAGIC Lab at Anam Campus of Korea University in Seongbuk-gu, Seoul on September 20.
The two organizations will suggest an early infectious disease diagnosis and treatment method via the Aibril Infectious Disease Diagnosis Service Platform based on Watson for the first time in the world in accordance with this MOU.
Up to now, medical services based on artificial intelligence (AI) have been developed to mainly diagnose cancers. But with respect to infectious diseases such as Middle East Respiratory Syndrome (MERS) and cholera, no organization has ever provided medical services based on artificial intelligence in the world.
SK Holdings C&C is planning to actively make a foray into the world medical AI service market by commercializing the Aibril Infectious Disease Diagnosis Service as soon as possible based on the MOU.
In the future, when meeting patients suspected of having infectious diseases, medical personnel will be able to connect to the Aibril Infectious Disease Diagnosis Service and feed the patients’ symptoms into the service system with PCs, tablet PCs and smartphones among other devices and Aibril will suggest possible infectious diseases and treatment methods. In particular, both organizations are planning to have the service utilized at primary medical institutions such as clinics and small and mid-sized hospitals across the nation.